Please login to the form below
Tobi Podhaler
This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.
NICE backs Novartis/ ThromboGenics’ eye drug
ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.
Latest news
-
NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest
The limited recommendation takes into account that the Tobi Podhaler and Colobreathe are dry powder versions of already available nebulised products. ... form. The Tobi Podhaler should only be used in cystic fibrosis patients for whom nebulised
-
NICE backs two cystic fibrosis treatments for NHS use
Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price. Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS in England and Wales ... The final draft guidance from the
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
-
Senior Medical Writer
-
Competitive salary and benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
-
Account Director, Medical Education
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
-
Senior Medical Writer
-
Salary TBC
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
Subscribe to our email news alerts
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
- The Pharma Brand Planners’ Blog: Part 1
- Novartis makes case for gene therapy Zolgensma in SMA
- Adding different perspectives to scientific communications at Porterhouse Medical
- Hemlibra off to a flyer as Roche raises 2019 forecasts
PMHub
Real Science Communications
Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
